Avalo Therapeutics AVTX Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Aclaris TherapeuticsACRS

$1.85M-21.8%

AnaptysBio, Inc.ANAB

$13.61K-99.9%

AbCellera Biologics Inc.ABCL

$143.22M+119%

Alumis Inc.ALMS

$35.66M+1,881%

ImmunityBio, Inc.IBRX

$40.77M+0.5%

Oruka Therapeutics, Inc.ORKA

$1.81M+90.8%

FAQ

What is Avalo Therapeutics's operating lease liabilities (total)?

Avalo Therapeutics (AVTX) reported operating lease liabilities (total) of $242K in Q2 2026.

How has Avalo Therapeutics's operating lease liabilities (total) changed year-over-year?

Avalo Therapeutics's operating lease liabilities (total) decreased by 64.4% year-over-year, from $679K to $242K.

What is the long-term trend for Avalo Therapeutics's operating lease liabilities (total)?

Over 5 years (2020 to 2025), Avalo Therapeutics's operating lease liabilities (total) has grown at a -21.8% compound annual growth rate (CAGR), from $1.46M to $427K.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.